CN113354687A - Organic electroluminescent material and device - Google Patents

Organic electroluminescent material and device Download PDF

Info

Publication number
CN113354687A
CN113354687A CN202110243480.4A CN202110243480A CN113354687A CN 113354687 A CN113354687 A CN 113354687A CN 202110243480 A CN202110243480 A CN 202110243480A CN 113354687 A CN113354687 A CN 113354687A
Authority
CN
China
Prior art keywords
group
ring
compound
integer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110243480.4A
Other languages
Chinese (zh)
Inventor
沃尔特·耶格尔
蔡瑞益
亚力克西·鲍里索维奇·迪亚特金
皮埃尔-吕克·T·布德罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universal Exhibition Co
Universal Display Corp
Original Assignee
Universal Exhibition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/179,952 external-priority patent/US20210288269A1/en
Application filed by Universal Exhibition Co filed Critical Universal Exhibition Co
Publication of CN113354687A publication Critical patent/CN113354687A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0033Iridium compounds
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30Coordination compounds
    • H10K85/341Transition metal complexes, e.g. Ru(II)polypyridine complexes
    • H10K85/342Transition metal complexes, e.g. Ru(II)polypyridine complexes comprising iridium
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/18Metal complexes
    • C09K2211/185Metal complexes of the platinum group, i.e. Os, Ir, Pt, Ru, Rh or Pd

Abstract

The present invention relates to organic electroluminescent materials and devices. Novel iridium and platinum complexes containing heterocyclic benzo-fused ligands are provided. The disclosed compounds can include ligands having the structure of formula ILA
Figure DDA0002963167860000011
Formulations comprising these novel iridium and platinum complexes are also provided. OLEDs and related consumer products utilizing these novel iridium and platinum complexes are also provided.

Description

Organic electroluminescent material and device
Priority of united states provisional application No. 62/986,026 filed 3/6/2020 and united states provisional application No. 63/082,774 filed 9/24/2020, which are hereby incorporated by reference in their entireties, are claimed in this application under 35 u.s.c. § 119 (e).
Technical Field
The present disclosure relates generally to organometallic compounds and formulations and various uses thereof, including as emitters in devices such as organic light emitting diodes and related electronic devices.
Background
Photovoltaic devices utilizing organic materials are becoming increasingly popular for a variety of reasons. Many of the materials used to make such devices are relatively inexpensive, and therefore organic photovoltaic devices have the potential for cost advantages over inorganic devices. In addition, the inherent properties of organic materials (e.g., their flexibility) may make them more suitable for particular applications, such as fabrication on flexible substrates. Examples of organic optoelectronic devices include organic light emitting diodes/devices (OLEDs), organic phototransistors, organic photovoltaic cells, and organic photodetectors. For OLEDs, organic materials may have performance advantages over conventional materials.
OLEDs utilize organic thin films that emit light when a voltage is applied across the device. OLEDs are becoming an increasingly interesting technology for applications such as flat panel displays, lighting and backlighting.
One application of phosphorescent emissive molecules is in full color displays. Industry standards for such displays require pixels adapted to emit a particular color, known as a "saturated" color. In particular, these standards require saturated red, green, and blue pixels. Alternatively, OLEDs can be designed to emit white light. In conventional liquid crystal displays, an absorptive filter is used to filter the emission from a white backlight to produce red, green, and blue emissions. The same technique can also be used for OLEDs. The white OLED may be a single emission layer (EML) device or a stacked structure. Color can be measured using CIE coordinates well known in the art.
Disclosure of Invention
Novel pt (ii) complexes comprising tetradentate pyrimidine and pyrazine ligands are disclosed.
In one aspect, the present disclosure provides a compound comprising a ligand L having the structure of formula IA
Figure BDA0002963167840000021
Wherein:
ring a is a 6-membered aromatic ring;
ring D is a monocyclic or polycyclic fused ring system comprising one or more 5-or 6-membered carbocyclic or heterocyclic rings;
k is selected from the group consisting of: a direct bond, O and S;
RArepresents zero substitution, mono substitution, or up to the maximum permissible substitution of its associated ring;
RDrepresents a disubstituted or up to the maximum permissible substitution of its associated ring;
at least two adjacent RDForm a structure of formula II fused with D
Figure BDA0002963167840000022
Z1Selected from the group consisting of: o, S, Se, NR, CRR 'and SiRR';
Z2is N;
each RA、RB、RDR, R' and R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, oxyboronyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof;
the ligand LAComplexed with a metal M through a dotted line to form a 5-membered chelate ring;
m is selected from the group consisting of: ir, Rh, Re, Ru, Os, Pt, Pd, Au and Cu;
m may coordinate to other ligands;
LAcan be linked to other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
RA、RB、RDAny two of R and R' may be joined or fused to form a ring, and RA、RDAny of R and R' may be joined or fused to R "to form a ring.
In another aspect, the present disclosure provides a composition comprising a ligand L as described hereinAA formulation of the compound of (1).
In another aspect, the present disclosure provides an OLED having an organic layer containing a ligand L as described hereinAThe compound of (1).
In another aspect, the present disclosure provides a consumer product comprising an OLED having an organic layer comprising a ligand L as described hereinAThe compound of (1).
Drawings
Fig. 1 shows an organic light emitting device.
Fig. 2 shows an inverted organic light emitting device without a separate electron transport layer.
Detailed Description
A. Term(s) for
Unless otherwise specified, the following terms as used herein are defined as follows:
as used herein, the term "organic" includes polymeric materials and small molecule organic materials that may be used to fabricate organic optoelectronic devices. "Small molecule" refers to any organic material that is not a polymer, and "small molecules" may actually be quite large. In some cases, the small molecule may include a repeat unit. For example, the use of long chain alkyl groups as substituents does not remove a molecule from the "small molecule" class. Small molecules can also be incorporated into polymers, for example as pendant groups on the polymer backbone or as part of the backbone. Small molecules can also serve as the core moiety of a dendrimer, which consists of a series of chemical shells built on the core moiety. The core moiety of the dendrimer may be a fluorescent or phosphorescent small molecule emitter. Dendrimers can be "small molecules," and all dendrimers currently used in the OLED art are considered small molecules.
As used herein, "top" means furthest from the substrate, and "bottom" means closest to the substrate. Where a first layer is described as being "disposed" over "a second layer, the first layer is disposed farther from the substrate. Other layers may be present between the first and second layers, unless it is specified that the first layer is "in contact with" the second layer. For example, a cathode may be described as "disposed over" an anode even though various organic layers are present between the cathode and the anode.
As used herein, "solution processable" means capable of being dissolved, dispersed or transported in and/or deposited from a liquid medium in the form of a solution or suspension.
A ligand may be referred to as "photoactive" when it is believed that the ligand contributes directly to the photoactive properties of the emissive material. A ligand may be referred to as "ancillary" when it is believed that the ligand does not contribute to the photoactive properties of the emissive material, but the ancillary ligand may alter the properties of the photoactive ligand.
As used herein, and as will be generally understood by those skilled in the art, if the first energy level is closer to the vacuum energy level, the first "Highest Occupied Molecular Orbital" (HOMO) or "Lowest Unoccupied Molecular Orbital" (LUMO) energy level is "greater than" or "higher than" the second HOMO or LUMO energy level. Since Ionization Potential (IP) is measured as negative energy relative to vacuum level, a higher HOMO level corresponds to an IP with a smaller absolute value (less negative IP). Similarly, a higher LUMO energy level corresponds to an Electron Affinity (EA) with a smaller absolute value (a less negative EA). On a conventional energy level diagram with vacuum levels at the top, the LUMO energy level of a material is higher than the HOMO energy level of the same material. The "higher" HOMO or LUMO energy level appears closer to the top of this figure than the "lower" HOMO or LUMO energy level.
As used herein, and as will be generally understood by those skilled in the art, a first work function is "greater than" or "higher than" a second work function if the first work function has a higher absolute value. Since the work function is typically measured as negative relative to the vacuum level, this means that the "higher" work function is more negative (more negative). On a conventional energy level diagram with vacuum level at the top, the "higher" work function is illustrated as being farther from the vacuum level in the downward direction. Thus, the definitions of HOMO and LUMO energy levels follow a different rule than work functions.
The terms "halo," "halogen," and "halo" are used interchangeably and refer to fluorine, chlorine, bromine, and iodine.
The term "acyl" refers to a substituted carbonyl group (C (O) -Rs)。
The term "ester" refers to a substituted oxycarbonyl group (-O-C (O) -R)sor-C (O) -O-Rs) A group.
The term "ether" means-ORsA group.
The terms "thio" or "thioether" are used interchangeably and refer to-SRsA group.
The term "sulfinyl" refers to-S (O) -RsA group.
The term "sulfonyl" refers to-SO2-RsA group.
The term "phosphino" refers to-P (R)s)3Group, wherein each RsMay be the same or different.
The term "silyl" refers to-Si (R)s)3Group, wherein each RsMay be the same or different.
The term "oxyboronyl" refers to-B (R)s)2Group or Lewis adduct thereof (R) -B (R)s)3Group, wherein RsMay be the same or different.
In each of the above, RsMay be hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkeneAryl, heteroaryl, and combinations thereof. Preferred RsSelected from the group consisting of: alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
The term "alkyl" refers to and includes straight and branched chain alkyl groups. Preferred alkyl groups are those containing from one to fifteen carbon atoms and include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, and the like. In addition, the alkyl group may be optionally substituted.
The term "cycloalkyl" refers to and includes monocyclic, polycyclic and spiroalkyl groups. Preferred cycloalkyl groups are those containing 3 to 12 ring carbon atoms and include cyclopropyl, cyclopentyl, cyclohexyl, bicyclo [3.1.1] heptyl, spiro [4.5] decyl, spiro [5.5] undecyl, adamantyl, and the like. In addition, the cycloalkyl group may be optionally substituted.
The term "heteroalkyl" or "heterocycloalkyl" refers to an alkyl or cycloalkyl group, respectively, having at least one carbon atom replaced with a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. In addition, heteroalkyl or heterocycloalkyl groups may be optionally substituted.
The term "alkenyl" refers to and includes straight and branched chain alkenyl groups. An alkenyl group is essentially an alkyl group that includes at least one carbon-carbon double bond in the alkyl chain. Cycloalkenyl is essentially cycloalkyl that includes at least one carbon-carbon double bond in the cycloalkyl ring. The term "heteroalkenyl" as used herein refers to an alkenyl group having at least one carbon atom replaced with a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. Preferred alkenyl, cycloalkenyl or heteroalkenyl groups are those containing from two to fifteen carbon atoms. In addition, the alkenyl, cycloalkenyl or heteroalkenyl groups may be optionally substituted.
The term "alkynyl" refers to and includes straight and branched chain alkynyl groups. Alkynyl is essentially an alkyl group comprising at least one carbon-carbon triple bond in the alkyl chain. Preferred alkynyl groups are those containing from two to fifteen carbon atoms. In addition, alkynyl groups may be optionally substituted.
The terms "aralkyl" or "arylalkyl" are used interchangeably and refer to an alkyl group substituted with an aryl group. In addition, the aralkyl group may be optionally substituted.
The term "heterocyclyl" refers to and includes both aromatic and non-aromatic cyclic groups containing at least one heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. Aromatic heterocyclic groups may be used interchangeably with heteroaryl groups. Preferred non-aromatic heterocyclic groups are heterocyclic groups containing 3 to 7 ring atoms including at least one heteroatom and include cyclic amines such as morpholinyl, piperidinyl, pyrrolidinyl and the like, and cyclic ethers/thioethers such as tetrahydrofuran, tetrahydropyran, tetrahydrothiophene and the like. In addition, the heterocyclic group may be optionally substituted.
The term "aryl" refers to and includes monocyclic aromatic hydrocarbon radicals and polycyclic aromatic ring systems. Polycyclic rings can have two or more rings in which two carbons are common to two adjoining rings (the rings are "fused"), wherein at least one of the rings is an aromatic hydrocarbyl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryls, heterocyclics, and/or heteroaryls. Preferred aryl groups are those containing from six to thirty carbon atoms, preferably from six to twenty carbon atoms, more preferably from six to twelve carbon atoms. Especially preferred are aryl groups having six carbons, ten carbons, or twelve carbons. Suitable aryl groups include phenyl, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, perylene,
Figure BDA0002963167840000051
Perylene and azulene, preferably phenyl, biphenyl, terphenyl, triphenylene, fluorene and naphthalene. In addition, the aryl group may be optionally substituted.
The term "heteroaryl" refers to and includes monocyclic aromatic groups and polycyclic aromatic ring systems that include at least one heteroatom. Heteroatoms include, but are not limited to O, S, N, P, B, Si and Se. In many cases O, S or N are preferred heteroatoms. Monocyclic heteroaromatic systems are preferably monocyclic with 5 or 6 ring atoms, and rings may have one to six heteroatoms. A heteropolycyclic system can have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused"), wherein at least one of the rings is heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryls, heterocycles and/or heteroaryls. The heterocyclic aromatic ring system may have one to six heteroatoms per ring of the polycyclic aromatic ring system. Preferred heteroaryl groups are those containing from three to thirty carbon atoms, preferably from three to twenty carbon atoms, more preferably from three to twelve carbon atoms. Suitable heteroaryl groups include dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzothienopyridine, and selenenopyridine, preferably dibenzothiophene, and benzothiophene, Dibenzofurans, dibenzoselenophenes, carbazoles, indolocarbazoles, imidazoles, pyridines, triazines, benzimidazoles, 1, 2-azaborines, 1, 3-azaborines, 1, 4-azaborines, borazines, and aza analogs thereof. In addition, the heteroaryl group may be optionally substituted.
Of the aryl and heteroaryl groups listed above, triphenylene, naphthalene, anthracene, dibenzothiophene, dibenzofuran, dibenzoselenophene, carbazole, indolocarbazole, imidazole, pyridine, pyrazine, pyrimidine, triazine, and benzimidazole are of particular interest, as well as their respective corresponding aza analogues.
The terms alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aralkyl, heterocyclyl, aryl, and heteroaryl, as used herein, are independently unsubstituted or independently substituted with one or more general substituents.
In many cases, typical substituents are selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, boroxy, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, boroxy, and combinations thereof.
In some cases, preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, oxyboronyl, and combinations thereof.
In some cases, more preferred general substituents are selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, alkoxy, aryloxy, amino, silyl, aryl, heteroaryl, thio, and combinations thereof.
In other cases, most preferred general substituents are selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
The terms "substituted" and "substitution" mean that a substituent other than H is bonded to the relevant position, e.g., carbon or nitrogen. For example, when R is1When representing a single substitution, then one R1Must not be H (i.e., substituted). Similarly, when R is1When representing disubstituted, then two R1Must not be H. Similarly, when R is1When represents zero or no substitution, R1For example, hydrogen may be available in valence number to a ring atom (e.g., a carbon atom of benzene and a nitrogen atom in pyrrole), or may represent nothing only to a ring atom having a fully saturated valence number (e.g., a nitrogen atom in pyridine). The maximum number of substitutions possible in a ring structure will depend on the total number of available valences in the ring atoms.
As used herein, "a combination thereof" means that one or more members of the applicable list are combined to form a known or chemically stable arrangement that one of ordinary skill in the art can envision from the applicable list. For example, alkyl and deuterium can be combined to form a partially or fully deuterated alkyl; halogen and alkyl may combine to form haloalkyl substituents; and halogen, alkyl, and aryl groups may be combined to form haloaralkyl groups. In one example, the term substituted includes combinations of two to four of the listed groups. In another example, the term substitution includes a combination of two to three groups. In yet another example, the term substitution includes a combination of two groups. Preferred combinations of substituents are those containing up to fifty atoms other than hydrogen or deuterium, or those containing up to forty atoms other than hydrogen or deuterium, or those containing up to thirty atoms other than hydrogen or deuterium. In many cases, a preferred combination of substituents will include up to twenty atoms that are not hydrogen or deuterium.
The term "aza" in the fragment described herein, i.e., aza-dibenzofuran, aza-dibenzothiophene, etc., means that one or more of the C-H groups in the corresponding aromatic ring can be replaced by a nitrogen atom, for example and without any limitation, azatriphenylene encompasses dibenzo [ f, H ] quinoxaline and dibenzo [ f, H ] quinoline. Other nitrogen analogs of the aza-derivatives described above can be readily envisioned by one of ordinary skill in the art, and all such analogs are intended to be encompassed by the term as set forth herein.
As used herein, "deuterium" refers to an isotope of hydrogen. Deuterated compounds can be readily prepared using methods known in the art. For example, U.S. patent No. 8,557,400, patent publication No. WO 2006/095951, and U.S. patent application publication No. US 2011/0037057 (which are incorporated herein by reference in their entirety) describe the preparation of deuterium substituted organometallic complexes. With further reference to \37154min (Ming Yan) et al, Tetrahedron (Tetrahedron)2015,71,1425-30 and azrote (Atzrodt) et al, german applied chemistry (angelw. chem. int. ed.) (review) 2007,46,7744-65, which are incorporated by reference in their entirety, describe efficient routes for deuteration of methylene hydrogens in benzylamines and replacement of aromatic ring hydrogens with deuterium, respectively.
It is understood that when a molecular fragment is described as a substituent or otherwise attached to another moiety, its name can be written as if it were a fragment (e.g., phenyl, phenylene, naphthyl, dibenzofuranyl) or as if it were an entire molecule (e.g., benzene, naphthalene, dibenzofuran). As used herein, these different named substituents or the manner of linking the fragments are considered equivalent.
In some cases, a pair of adjacent substituents may optionally join or be fused to form a ring. Preferred rings are five-, six-or seven-membered carbocyclic or heterocyclic rings, including both cases where a portion of the ring formed by the pair of substituents is saturated and where a portion of the ring formed by the pair of substituents is unsaturated. As used herein, "adjacent" means that the two substituents involved can be on the same ring next to each other, or on two adjacent rings having two nearest available substitutable positions (e.g., the 2, 2' positions in biphenyl or the 1, 8 positions in naphthalene), so long as they can form a stable fused ring system.
B. Compounds of the present disclosure
In one aspect, the present disclosure provides a compound comprising a ligand L having the structure of formula IA
Figure BDA0002963167840000081
Wherein:
ring a is a 6-membered aromatic ring;
ring D is a monocyclic or polycyclic fused ring system comprising one or more 5-or 6-membered carbocyclic or heterocyclic rings;
k is selected from the group consisting of: a direct bond, O and S;
RArepresents zero substitution, mono substitution, or up to the maximum permissible substitution of its associated ring;
RDrepresents a disubstituted or up to the maximum permissible substitution of its associated ring;
at least two adjacent RDForming a structure of formula II fused to D;
Figure BDA0002963167840000082
Z1selected from the group consisting of: o, S, Se, NR, CRR 'and SiRR';
Z2is N;
each RA、RB、RDR, R' and R "are independently hydrogen or a substituent selected from the group consisting of the general substituents disclosed above;
the ligand LAComplexed with a metal M through a dotted line to form a 5-membered chelate ring;
m is selected from the group consisting of: ir, Rh, Re, Ru, Os, Pt, Pd, Au and Cu;
m may coordinate to other ligands;
LAcan be linked to other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
RA、RB、RDAny two of R and R' may be joined or fused to form a ring, and RA、RDAny of R and R' may be joined or fused to R "to form a ring.
In some embodiments, each R isA、RB、RDR and R' are independently hydrogen or the general substituents disclosed above.
In some embodiments, RBSelected from the group consisting of the preferred general substituents disclosed above.
In some embodiments, RBSelected from the group consisting of the following list a:
Figure BDA0002963167840000091
in some embodiments, ring D is selected from the group consisting of: phenyl, naphthalene, anthracene, benzofuran, benzothiophene, dibenzofuran, dibenzothiophene, and aza variants thereof.
In some embodiments, ring a is selected from the group consisting of: pyridine, pyrimidine, pyridazine, quinoline, isoquinoline, quinoxaline, quinazoline, thienopyridine, thienopyrimidine, thienopyridazine, azabiphenyl furan, azabiphenyl thiophene, azabenzofuran, and azabenzothiophene.
In some embodiments, Z1Selected from the group consisting of: o, S and NR.
In some embodiments, K is a direct bond.
In some embodiments, K is O or S.
In some embodiments, the structure of formula II is selected from the group consisting of table B below:
Figure BDA0002963167840000092
Figure BDA0002963167840000101
Figure BDA0002963167840000111
in some embodiments, M is Ir.
In some embodiments, M is Pd or Pt.
In some embodiments, LASelected from the group consisting of the following list C:
Figure BDA0002963167840000112
Figure BDA0002963167840000121
Figure BDA0002963167840000131
Z1'o, S, CH or NCH3 Z2'、Z3'、Z4'Either C or N
Figure BDA0002963167840000141
Figure BDA0002963167840000151
Figure BDA0002963167840000161
Figure BDA0002963167840000171
Figure BDA0002963167840000181
Figure BDA0002963167840000191
Figure BDA0002963167840000201
Wherein Z1'O, S or NCH3;Z2'、Z3'、Z4'C or N; and Z is5'=O、N、S、Si(CH3)2Or C (CH)3)2
In some embodiments, LAIs selected from the group consisting of LAi-mWherein i is an integer from 1 to 2100 and m is an integer from 1 to 66, wherein LAi-mHaving L as defined in Table 1 belowAi-1To LAi-66The structure of (1):
Figure BDA0002963167840000202
Figure BDA0002963167840000211
Figure BDA0002963167840000221
Figure BDA0002963167840000231
Figure BDA0002963167840000241
Figure BDA0002963167840000251
wherein each RAAnd RBDefined in table 2 below:
Figure BDA0002963167840000252
Figure BDA0002963167840000261
Figure BDA0002963167840000271
Figure BDA0002963167840000281
Figure BDA0002963167840000291
Figure BDA0002963167840000301
Figure BDA0002963167840000311
Figure BDA0002963167840000321
Figure BDA0002963167840000331
Figure BDA0002963167840000341
wherein R isA1To RA70Having the structure in the following list D:
Figure BDA0002963167840000342
Figure BDA0002963167840000343
Figure BDA0002963167840000351
Figure BDA0002963167840000361
Figure BDA0002963167840000371
wherein R isB1To RB30Has the advantages ofThe following structure in Table E:
Figure BDA0002963167840000372
Figure BDA0002963167840000381
in some embodiments, the compound has formula M (L)A)p(LB)q(LC)rWherein L isBAnd LCEach is a bidentate ligand; and wherein p is 1,2 or 3; q is 0, 1 or 2; r is 0, 1 or 2; and p + q + r is the oxidation state of the metal M.
In some embodiments, the compound has a formula selected from the group consisting of: ir (L)A)3、Ir(LA)(LB)2、Ir(LA)2(LB)、Ir(LA)2(LC) And Ir (L)A)(LB)(LC) (ii) a And wherein LA、LBAnd LCAre different from each other.
In some embodiments, the compound has the formula Pt (L)A)(LB) (ii) a And wherein LAAnd LBMay be the same or different.
In some embodiments, LAAnd LBLinked to form a tetradentate ligand.
In some embodiments, LAAnd LBLinked at two positions to form a macrocyclic tetradentate ligand.
In some embodiments, LBAnd LCEach independently selected from the group consisting of the following list F:
Figure BDA0002963167840000382
Figure BDA0002963167840000391
wherein:
t is B, Al, Ga or In;
Y1to Y13Each of which is independently selected from the group consisting of C and N;
y' is selected from the group consisting of: BR (BR)e、NRe、PRe、O、S、Se、C=O、S=O、SO2、CReRf、SiReRfAnd GeReRf
ReAnd RfMay be fused or joined to form a ring;
each Ra、Rb、RcAnd RdIndependently represent zero substitution, mono substitution, or up to the maximum allowed number of substitutions for its associated ring;
Ra1、Rb1、Rc1、Rd1、Ra、Rb、Rc、Rd、Reand RfEach of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, halo, alkyl, cycloalkyl, heteroalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; general substituents as defined herein; and is
Any two adjacent Ra、Rb、Rc、Rd、ReAnd RfMay be fused or joined to form a ring or to form a multidentate ligand.
In some embodiments, LBAnd LCEach independently selected from the group consisting of the following list G:
Figure BDA0002963167840000401
Figure BDA0002963167840000411
Figure BDA0002963167840000421
Figure BDA0002963167840000431
wherein:
Ra'、Rb' and Rc' each independently represents zero substitution, single substitution, or up to a maximum allowed number of substitutions for its associated ring;
Ra1、Rb1、Rc1、Ra、Rb、Rc、RN、Ra'、Rb' and RcEach of' is independently hydrogen or a substituent selected from the group consisting of: deuterium, halo, alkyl, cycloalkyl, heteroalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, boroxy, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, boroxy, and combinations thereof; and is
Two adjacent Ra'、Rb' and Rc' may be fused or joined to form a ring or to form a multidentate ligand.
In some embodiments, LBIs substituted or unsubstituted phenylpyridine.
In some embodiments, LBSelected from L defined byB1-LB270The group consisting of:
Figure BDA0002963167840000432
Figure BDA0002963167840000441
Figure BDA0002963167840000451
Figure BDA0002963167840000461
Figure BDA0002963167840000471
Figure BDA0002963167840000481
Figure BDA0002963167840000491
Figure BDA0002963167840000501
Figure BDA0002963167840000511
Figure BDA0002963167840000521
in some embodiments, LCIs a substituted or unsubstituted acetylacetonate.
In some embodiments, LCIs selected from the group consisting of LCj-IAnd LCj-IIWherein j is an integer from 1 to 1416, LCj-IFrom the compound LC1-ITo LC1416-IIn which the general numbering is as LCj-IBased on structure
Figure BDA0002963167840000522
And L isCj-IIFrom the compound LC1-IITo LC1416-IIIn which the general numbering is as LCj-IIBased on structure
Figure BDA0002963167840000523
Wherein L isCj-IAnd LCj-IIR of (A) to (B)201And R202Each independently defined in table 3 below:
Figure BDA0002963167840000524
Figure BDA0002963167840000531
Figure BDA0002963167840000541
Figure BDA0002963167840000551
Figure BDA0002963167840000561
Figure BDA0002963167840000571
Figure BDA0002963167840000581
Figure BDA0002963167840000591
Figure BDA0002963167840000601
wherein R isD1To RD246Having the structure in the following table I:
Figure BDA0002963167840000602
Figure BDA0002963167840000611
Figure BDA0002963167840000621
Figure BDA0002963167840000631
Figure BDA0002963167840000641
in some embodiments, LBkSelected from the group consisting of: l isB1、LB2、LB18、LB28、LB38、LB108、LB118、LB122、LB124、LB126、LB128、LB130、LB132、LB134、LB136、LB138、LB140、LB142、LB144、LB156、LB158、LB160、LB162、LB164、LB168、LB172、LB175、LB204、LB206、LB214、LB216、LB218、LB220、LB222、LB231、LB233、LB235、LB237、LB240、LB242、LB244、LB246、LB248、LB250、LB252、LB254、LB256、LB258、LB260、LB262、LB264、LB265、LB266、LB267、LB268、LB269And LB270
In some embodiments, LBkSelected from the group consisting of: l isB1、LB2、LB18、LB28、LB38、LB108、LB118、LB122、LB126、LB128、LB132、LB136、LB138、LB142、LB156、LB162、LB204、LB206、LB214、LB216、LB218、LB220、LB231、LB233、LB237、LB264、LB265、LB266、LB267、LB268、LB269And LB270
In some embodiments, when R corresponds to201And R202When selected from the following structures, LCj-IAnd LCj-IIEach independently selected from its corresponding group: rD1、RD3、RD4、RD5、RD9、RD10、RD17、RD18、RD20、RD22、RD37、RD40、RD41、RD42、RD43、RD48、RD49、RD50、RD54、RD55、RD58、RD59、RD78、RD79、RD81、RD87、RD88、RD89、RD93、RD116、RD117、RD118、RD119、RD120、RD133、RD134、RD135、RD136、RD143、RD144、RD145、RD146、RD147、RD149、RD151、RD154、RD155、RD161、RD175 RD190、RD193、RD200、RD201、RD206、RD210、RD214、RD215、RD216、RD218、RD219、RD220、RD227、RD237、RD241、RD242、RD245And RD246
In some embodiments, when R corresponds to201And R202When selected from the following structures, LCj-IAnd LCj-IIEach independently selected from its corresponding group: rD1、RD3、RD4、RD5、RD9、RD10、RD17、RD22、RD43、RD50、RD78、RD116、RD118、RD133、RD134、RD135、RD136、RD143、RD144、RD145、RD146、RD149、RD151、RD154、RD155、RD190、RD193、RD200、RD201、RD206、RD210、RD214、RD215、RD216、RD218、RD219、RD220、RD227、RD237、RD241、RD242、RD245And RD246
In some embodiments, LCj-IIndependently at each occurrence, selected from the group consisting of the following list J:
Figure BDA0002963167840000651
Figure BDA0002963167840000661
in some embodiments, the compound is selected from the group consisting of:
corresponding to each formula Ir (L)Ai-m)3I is an integer from 1 to 2100, m is an integer from 1 to 66, and compound-A-i-m is selected from the group consisting of Ir (L)A1-1)3To Ir (L)A2100-66)3A group of compounds;
corresponding to each formula Ir (L)Ai-m)(LBk)2I is an integer from 1 to 2100, m is an integer from 1 to 66, k is an integer from 1 to 270, and compound-B-i-m-k is selected from the group consisting of Ir (L)A1-1)(LB1)2To Ir (L)A2100-66)(LB270)2A group of compounds;
corresponding to each formula Ir (L)Ai-m)2(LBk) I is an integer from 1 to 2100, m is an integer from 1 to 66, k is an integer from 1 to 270, and compound-B' -i-m-k is selected from the group consisting of Ir (L)A1-1)2(LB1) To Ir (L)A2100-66)2(LB270) A group of compounds;
corresponding to each formula Ir (L)Ai-m)2(LCj-I) Is a compound of formula (I), I is an integer from 1 to 2100, m is an integer from 1 to 66, j is an integer from 1 to 1416, and the compound of formula (I) is selected from the group consisting of Ir (L)A1-1)2(LC1-I) To Ir (L)A2100-66)2(LC1416-I) A group of compounds; and
corresponding to each formula Ir (L)Ai-m)2(LCj-II) Is a compound of formula (I) -C-i-m-j-II, i is an integer from 1 to 2100, m is an integer from 1 to 66, j is an integer from 1 to 1416, and compound-C-i-m-j-II is selected from the group consisting of Ir (L)A1-1)2(LC1-II) To Ir (L)A2100-66)2(LC1416-II) A group of combinations thereof.
In some embodiments, the compound is selected from the group consisting of table K below:
Figure BDA0002963167840000671
Figure BDA0002963167840000681
Figure BDA0002963167840000691
Figure BDA0002963167840000701
Figure BDA0002963167840000711
Figure BDA0002963167840000721
in some embodiments, the compound has formula III:
Figure BDA0002963167840000722
wherein:
M1is Pd or Pt;
rings E and F are each independently a 5-or 6-membered carbocyclic or heterocyclic ring;
Z1and Z2Each independently is C or N;
K1and K2Each independently selected from the group consisting of: a direct bond, O and S, wherein K1And K2At least one of which is a direct bond;
L1、L2and L3Each independently selected from the group consisting of: a single bond, absent a bond, O, S, CR 'R ", SiR' R", BR ', CR ═ CR ", and NR', wherein L is1、L2And L3At least two of which are present;
REand RFEach independentlyDenotes zero substitution, mono substitution or at most the maximum allowed substitution for its associated ring;
R'、R”、REand RFEach of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof;
any two RA、RD、RE、RFR 'and R' may be joined or fused to form a ring when chemically feasible; and is
RA、RDK and rings A and D are all as defined above.
In some embodiments, ring E and ring F are both 6-membered aromatic rings.
In some embodiments, ring F is a 5-or 6-membered heteroaryl ring.
In some embodiments, L1Is O or CR' R ".
In some embodiments, Z2Is N and Z1Is C.
In some embodiments, Z2Is C and Z1Is N.
In some embodiments, L2Is a direct bond.
In some embodiments, L2Is NR'.
In some embodiments, K1And K2Are all direct bonds.
In some embodiments, the compound is selected from the group consisting of the structures in table L below:
Figure BDA0002963167840000731
Figure BDA0002963167840000741
Figure BDA0002963167840000751
wherein:
two adjacent RDForming a structure of formula II fused to D;
formula II
Figure BDA0002963167840000752
RxAnd RyEach selected from the group consisting of: alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, heteroaryl, and combinations thereof;
RGindependently at each occurrence is hydrogen or a substituent selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof; and is
RA、RB、RE、RF、Z1、Z2、K、L1Rings a and D are all as defined above.
In some embodiments, the compound is selected from the group consisting of list M below:
Figure BDA0002963167840000761
Figure BDA0002963167840000771
Figure BDA0002963167840000781
Figure BDA0002963167840000791
Figure BDA0002963167840000801
C. OLEDs and devices of the present disclosure
In another aspect, the present disclosure also provides an OLED device comprising a first organic layer comprising a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the OLED comprises an anode, a cathode, and an organic layer disposed between the anode and the cathode. The organic layer may contain a ligand LAThe ligand having a structure according to formula 1 described herein.
In some embodiments, the organic layer may be an emissive layer and the compound as described herein may be an emissive dopant or a non-emissive dopant.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises a triphenylene comprising a benzo-fused thiophene or a benzo-fused furan, wherein any substituent in the host is a non-fused substituent independently selected from the group consisting of: cnH2n+1、OCnH2n+1、OAr1、N(CnH2n+1)2、N(Ar1)(Ar2)、CH=CH-CnH2n+1、C≡CCnH2n+1、Ar1、Ar1-Ar2、CnH2n-Ar1Or no substituent, wherein n is 1 to 10; and wherein Ar1And Ar2Independently selected from the group consisting of: benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises at least one chemical group selected from the group consisting of: triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5, 9-dioxa-13 b-boronaphtho [3,2,1-de ] anthracene, aza-triphenylene, aza-carbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, and aza- (5, 9-dioxa-13 b-boronaphtho [3,2,1-de ] anthracene).
In some embodiments, the body may be selected from the group of bodies consisting of the structures in list N below:
Figure BDA0002963167840000802
Figure BDA0002963167840000811
Figure BDA0002963167840000821
Figure BDA0002963167840000822
and combinations thereof.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises a metal complex.
In some embodiments, a compound as described herein may be a sensitizer; wherein the device may further comprise a receptor; and wherein the receptor may be selected from the group consisting of: fluorescent emitters, delayed fluorescent emitters, and combinations thereof.
In yet another aspect, the OLEDs of the present disclosure can further comprise an emissive region comprising a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the emissive region may comprise a compound of the present disclosure.
In some embodiments, at least one of the anode, cathode, or new layer disposed over the organic emissive layer serves as an enhancement layer. The enhancement layer includes a plasmonic material exhibiting surface plasmon resonance that couples non-radiatively to the emitter material and transfers excited state energy from the emitter material to a non-radiative mode of surface plasmon polaritons. The enhancement layer is disposed at a distance from the organic emissive layer that does not exceed a threshold distance, wherein the emitter material has an overall non-radiative decay rate constant and an overall radiative decay rate constant due to the presence of the enhancement layer, and the threshold distance is where the overall non-radiative decay rate constant equals the overall radiative decay rate constant. In some embodiments, the OLED further comprises an outcoupling layer. In some embodiments, the outcoupling layer is disposed on the enhancement layer on the opposite side of the organic emission layer. In some embodiments, the outcoupling layer is disposed on the opposite side of the emission layer from the enhancement layer, but is still capable of outcoupling energy from surface plasmon modes of the enhancement layer. The outcoupling layer scatters energy from surface plasmon polaritons. In some embodiments, this energy is scattered into free space as photons. In other embodiments, energy is scattered from a surface plasmon mode of the device into other modes, such as, but not limited to, an organic waveguide mode, a substrate mode, or another waveguide mode. If the energy is scattered into a non-free space mode of the OLED, other outcoupling schemes can be incorporated to extract the energy into free space. In some embodiments, one or more intervening layers may be disposed between the enhancement layer and the outcoupling layer. Examples of intervening layers may be dielectric materials, including organic, inorganic, perovskite, oxides, and may include stacks and/or mixtures of these materials.
The enhancement layer changes the effective characteristics of the medium in which the emitter material resides, thereby causing any or all of the following: reduced emissivity, linear change in emission, angular change in emission intensity, change in emitter material stability, change in OLED efficiency, and reduced roll-off efficiency of the OLED device. Placing the enhancement layer on the cathode side, the anode side, or both sides results in an OLED device that takes advantage of any of the effects described above. In addition to the specific functional layers mentioned herein and illustrated in the various OLED examples shown in the figures, OLEDs according to the present disclosure may also include any other functional layers that are common in OLEDs.
The enhancement layer may comprise a plasmonic material, an optically active metamaterial or a hyperbolic metamaterial. As used herein, a plasmonic material is a material in which the real part of the dielectric constant crosses zero in the visible or ultraviolet region of the electromagnetic spectrum. In some embodiments, the plasmonic material comprises at least one metal. In such embodiments, the metal may include at least one of: ag. Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, Ca, alloys or mixtures of these materials, and stacks of these materials. In general, a metamaterial is a medium composed of different materials, wherein the medium as a whole acts differently than the sum of its material parts. Specifically, we define an optically active metamaterial as a material having both negative permittivity and negative permeability. On the other hand, hyperbolic metamaterials are anisotropic media in which the permittivity or permeability has different signs for different spatial directions. Optically active metamaterials and hyperbolic metamaterials are strictly distinguished from many other photonic structures, such as Distributed Bragg reflectors ("DBRs"), because the medium should appear uniform in the propagation direction on the length scale of the optical wavelength. Using terminology understood by those skilled in the art: the dielectric constant of the metamaterial in the propagation direction can be described by an effective medium approximation. Plasmonic and metamaterial materials provide a means for controlling light propagation that can enhance OLED performance in a variety of ways.
In some embodiments, the reinforcement layer is provided as a planar layer. In other embodiments, the enhancement layer has features of wavelength size arranged periodically, quasi-periodically, or randomly, or features of sub-wavelength size arranged periodically, quasi-periodically, or randomly. In some embodiments, the wavelength-sized features and the sub-wavelength-sized features have sharp edges.
In some embodiments, the outcoupling layer has features of wavelength size that are arranged periodically, quasi-periodically, or randomly, or features of sub-wavelength size that are arranged periodically, quasi-periodically, or randomly. In some embodiments, the outcoupling layer may be composed of a plurality of nanoparticles, and in other embodiments, the outcoupling layer is composed of a plurality of nanoparticles disposed over the material. In these embodiments, the out-coupling may be adjusted by at least one of the following: varying a size of the plurality of nanoparticles, varying a shape of the plurality of nanoparticles, varying a material of the plurality of nanoparticles, adjusting a thickness of the material, varying a refractive index of the material or an additional layer disposed on the plurality of nanoparticles, varying a thickness of the enhancement layer, and/or varying a material of the enhancement layer. The plurality of nanoparticles of the device may be formed from at least one of: a metal, a dielectric material, a semiconductor material, a metal alloy, a mixture of dielectric materials, a stack or a laminate of one or more materials, and/or a core of one type of material and coated with a shell of another type of material. In some embodiments, the outcoupling layer is composed of at least metal nanoparticles, wherein the metal is selected from the group consisting of: ag. Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, Ca, alloys or mixtures of these materials, and stacks of these materials. The plurality of nanoparticles may have an additional layer disposed thereon. In some embodiments, an outcoupling layer may be used to adjust the polarization of the emission. Varying the size and periodicity of the outcoupling layer can select the type of polarization that is preferentially outcoupled to air. In some embodiments, the outcoupling layer also serves as an electrode of the device.
In yet another aspect, the present disclosure also provides a consumer product comprising an Organic Light Emitting Device (OLED) having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer can comprise a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the consumer product comprises an OLED, the organic light emitting device having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer can comprise a compound of the present disclosure as described herein.
In some embodiments, the consumer product may be one of the following: a flat panel display, a computer monitor, a medical monitor, a television, a billboard, a light for interior or exterior lighting and/or signaling, a heads-up display, a fully or partially transparent display, a flexible display, a laser printer, a telephone, a cellular telephone, a tablet, a phablet, a Personal Digital Assistant (PDA), a wearable device, a laptop computer, a digital camera, a video camera, a viewfinder, a microdisplay at a diagonal of less than 2 inches, a 3-D display, a virtual reality or augmented reality display, a vehicle, a video wall containing multiple displays tiled together, a theater or stadium screen, a phototherapy device, and a sign.
Generally, an OLED comprises at least one organic layer disposed between and electrically connected to an anode and a cathode. When current is applied, the anode injects holes and the cathode injects electrons into the organic layer. The injected holes and electrons each migrate toward the oppositely charged electrode. When an electron and a hole are located on the same molecule, an "exciton," which is a localized electron-hole pair with an excited energy state, is formed. When the exciton relaxes by a light emission mechanism, light is emitted. In some cases, the exciton may be localized on an excimer (eximer) or an exciplex. Non-radiative mechanisms (such as thermal relaxation) may also occur, but are generally considered undesirable.
Several OLED materials and configurations are described in U.S. patent nos. 5,844,363, 6,303,238, and 5,707,745, which are incorporated herein by reference in their entirety.
The initial OLEDs used emissive molecules that emit light from a singlet state ("fluorescence"), as disclosed, for example, in U.S. patent No. 4,769,292, which is incorporated by reference in its entirety. Fluorescence emission typically occurs in a time frame of less than 10 nanoseconds.
More recently, OLEDs having emissive materials that emit light from the triplet state ("phosphorescence") have been demonstrated. Baldo et al, "high efficiency Phosphorescent Emission from Organic Electroluminescent Devices" (Nature), 395, 151-154,1998 ("Baldo-I"); and baldo et al, "Very high-efficiency green organic light-emitting devices based on electrophosphorescence (Very high-efficiency green organic light-emitting devices-based on electrophosphorescence)", applied physical promo (appl. phys. lett.), volume 75, stages 3,4-6 (1999) ("baldo-II"), which are incorporated by reference in their entirety. Phosphorescence is described in more detail in U.S. Pat. No. 7,279,704, columns 5-6, which is incorporated by reference.
Fig. 1 shows an organic light emitting device 100. The figures are not necessarily to scale. Device 100 can include substrate 110, anode 115, hole injection layer 120, hole transport layer 125, electron blocking layer 130, emissive layer 135, hole blocking layer 140, electron transport layer 145, electron injection layer 150, protective layer 155, cathode 160, and blocking layer 170. Cathode 160 is a composite cathode having a first conductive layer 162 and a second conductive layer 164. The device 100 may be fabricated by depositing the layers in sequence. The nature and function of these various layers, as well as example materials, are described in more detail in U.S. Pat. No. 7,279,704, columns 6-10, which is incorporated by reference.
More instances of each of these layers are available. For example, a flexible and transparent substrate-anode combination is disclosed in U.S. Pat. No. 5,844,363, which is incorporated by reference in its entirety. An example of a p-doped hole transport layer is doped with F at a molar ratio of 50:14TCNQ m-MTDATA as disclosed in U.S. patent application publication No. 2003/0230980, which is incorporated by reference in its entirety. Examples of luminescent and host materials are disclosed in U.S. Pat. No. 6,303,238 to Thompson et al, which is incorporated by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li at a molar ratio of 1:1, as disclosed in U.S. patent application publication No. 2003/0230980, which is incorporated by reference in its entirety. U.S. Pat. Nos. 5,703,436 and 5,707,745, which are incorporated by reference in their entirety, disclose examples of cathodes comprising composite cathodes having a thin layer of a metal (e.g., Mg: Ag) with an overlying transparent, conductive, sputter-deposited ITO layer. The theory and use of barrier layers is described in more detail in U.S. Pat. No. 6,097,147 and U.S. patent application publication No. 2003/0230980, which are incorporated by reference in their entiretyAnd (6) adding. Examples of injection layers are provided in U.S. patent application publication No. 2004/0174116, which is incorporated by reference in its entirety. A description of the protective layer may be found in U.S. patent application publication No. 2004/0174116, which is incorporated by reference in its entirety.
Fig. 2 shows an inverted OLED 200. The device includes a substrate 210, a cathode 215, an emissive layer 220, a hole transport layer 225, and an anode 230. The device 200 may be fabricated by depositing the layers in sequence. Because the most common OLED configuration has a cathode disposed above an anode, and device 200 has a cathode 215 disposed below an anode 230, device 200 may be referred to as an "inverted" OLED. Materials similar to those described with respect to device 100 may be used in corresponding layers of device 200. Fig. 2 provides one example of how some layers may be omitted from the structure of device 100.
The simple layered structure illustrated in fig. 1 and 2 is provided by way of non-limiting example, and it is to be understood that embodiments of the present disclosure may be used in conjunction with various other structures. The specific materials and structures described are exemplary in nature, and other materials and structures may be used. Functional OLEDs may be obtained by combining the various layers described in different ways, or the layers may be omitted entirely based on design, performance, and cost factors. Other layers not specifically described may also be included. Materials other than those specifically described may be used. Although many of the examples provided herein describe the various layers as comprising a single material, it is understood that combinations of materials may be used, such as mixtures of hosts and dopants, or more generally, mixtures. Further, the layer may have various sub-layers. The names given to the various layers herein are not intended to be strictly limiting. For example, in device 200, hole transport layer 225 transports holes and injects holes into emissive layer 220, and may be described as a hole transport layer or a hole injection layer. In one embodiment, an OLED may be described as having an "organic layer" disposed between a cathode and an anode. This organic layer may comprise a single layer, or may further comprise multiple layers of different organic materials as described, for example, with respect to fig. 1 and 2.
Structures and materials not specifically described may also be used, such as oleds (pleds) comprising polymeric materials, such as disclosed in U.S. patent No. 5,247,190 to frand (Friend), et al, which is incorporated by reference in its entirety. By way of further example, OLEDs having a single organic layer may be used. The OLEDs may be stacked, for example, as described in U.S. patent No. 5,707,745 to forrister (Forrest) et al, which is incorporated by reference in its entirety. The OLED structure may deviate from the simple layered structure illustrated in fig. 1 and 2. For example, the substrate may include an angled reflective surface to improve out-coupling (out-coupling), such as a mesa structure as described in U.S. Pat. No. 6,091,195 to Foster et al, and/or a pit structure as described in U.S. Pat. No. 5,834,893 to Boolean (Bulovic) et al, which are incorporated by reference in their entirety.
Any of the layers of the various embodiments may be deposited by any suitable method, unless otherwise specified. For organic layers, preferred methods include thermal evaporation, ink jetting (as described in U.S. Pat. Nos. 6,013,982 and 6,087,196, both incorporated by reference in their entirety), organic vapor deposition (OVPD) (as described in U.S. Pat. No. 6,337,102 to Foster et al, both incorporated by reference in their entirety), and deposition by Organic Vapor Jet Printing (OVJP) (as described in U.S. Pat. No. 7,431,968, incorporated by reference in its entirety). Other suitable deposition methods include spin coating and other solution-based processes. The solution-based process is preferably carried out in a nitrogen or inert atmosphere. For other layers, a preferred method includes thermal evaporation. Preferred patterning methods include deposition through a mask, cold welding (as described in U.S. Pat. nos. 6,294,398 and 6,468,819, which are incorporated by reference in their entirety), and patterning associated with some of the deposition methods such as inkjet and Organic Vapor Jet Printing (OVJP). Other methods may also be used. The material to be deposited may be modified to suit the particular deposition method. For example, substituents such as alkyl and aryl groups, branched or unbranched, and preferably containing at least 3 carbons, may be used in small molecules to enhance their ability to undergo solution processing. Substituents having 20 carbons or more may be used, and 3 to 20 carbons is a preferred range. A material with an asymmetric structure may have better solution processibility than a material with a symmetric structure because asymmetric materials may have a lower tendency to recrystallize. Dendrimer substituents may be used to enhance the ability of small molecules to undergo solution processing.
Devices fabricated according to embodiments of the present disclosure may further optionally include a barrier layer. One use of barrier layers is to protect the electrodes and organic layers from damage from exposure to hazardous substances in the environment including moisture, vapor, and/or gas. The barrier layer may be deposited on, under or beside the substrate, electrode, or on any other part of the device, including the edge. The barrier layer may comprise a single layer or multiple layers. The barrier layer may be formed by various known chemical vapor deposition techniques and may include compositions having a single phase and compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. The barrier layer may incorporate an inorganic compound or an organic compound or both. Preferred barrier layers comprise a mixture of polymeric and non-polymeric materials as described in U.S. patent No. 7,968,146, PCT patent application nos. PCT/US2007/023098 and PCT/US2009/042829, which are incorporated herein by reference in their entirety. To be considered a "mixture," the aforementioned polymeric and non-polymeric materials that make up the barrier layer should be deposited under the same reaction conditions and/or simultaneously. The weight ratio of polymeric material to non-polymeric material may be in the range of 95:5 to 5: 95. The polymeric material and the non-polymeric material may be produced from the same precursor material. In one example, the mixture of polymeric material and non-polymeric material consists essentially of polymeric silicon and inorganic silicon.
Devices manufactured according to embodiments of the present disclosure may be incorporated into a wide variety of electronic component modules (or units), which may be incorporated into a wide variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include display screens, lighting devices (e.g., discrete light source devices or lighting panels), etc., which may be utilized by end-user product manufacturers. The electronics module may optionally include drive electronics and/or a power source. Devices manufactured in accordance with embodiments of the present disclosure may be incorporated into a wide variety of consumer products having one or more electronic component modules (or units) incorporated therein. A consumer product comprising an OLED comprising a compound of the present disclosure in an organic layer in the OLED is disclosed. The consumer product shall include any kind of product comprising one or more light sources and/or one or more of some type of visual display. Some examples of such consumer products include flat panel displays, curved displays, computer monitors, medical monitors, televisions, billboards, lights for interior or exterior illumination and/or signaling, heads-up displays, fully or partially transparent displays, flexible displays, rollable displays, foldable displays, stretchable displays, laser printers, telephones, cellular telephones, tablet computers, tablet phones, Personal Digital Assistants (PDAs), wearable devices, laptop computers, digital cameras, video cameras, viewfinders, microdisplays (displays less than 2 inches diagonal), 3-D displays, virtual reality or augmented reality displays, vehicles, video walls containing multiple displays tiled together, theater or stadium screens, phototherapy devices, and signs. Various control mechanisms may be used to control devices made in accordance with the present disclosure, including passive matrices and active matrices. Many of the devices are intended to be used in a temperature range that is comfortable for humans, such as 18 ℃ to 30 ℃, and more preferably at room temperature (20-25 ℃), but can be used outside this temperature range (e.g., -40 ℃ to +80 ℃).
More details regarding OLEDs and the definitions described above can be found in U.S. patent No. 7,279,704, which is incorporated herein by reference in its entirety.
The materials and structures described herein may be applied to devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors may employ the materials and structures. More generally, organic devices such as organic transistors may employ the materials and structures.
In some embodiments, the OLED has one or more features selected from the group consisting of: flexible, rollable, foldable, stretchable, and bendable. In some embodiments, the OLED is transparent or translucent. In some embodiments, the OLED further comprises a layer comprising carbon nanotubes.
In some embodiments, the OLED further comprises a layer comprising a delayed fluorescence emitter. In some embodiments, the OLED comprises an RGB pixel arrangement or a white plus color filter pixel arrangement. In some embodiments, the OLED is a mobile device, a handheld device, or a wearable device. In some embodiments, the OLED is a display panel having a diagonal of less than 10 inches or an area of less than 50 square inches. In some embodiments, the OLED is a display panel having a diagonal of at least 10 inches or an area of at least 50 square inches. In some embodiments, the OLED is a lighting panel.
In some embodiments, the compound may be an emissive dopant. In some embodiments, the compounds may produce emission via phosphorescence, fluorescence, thermally activated delayed fluorescence (i.e., TADF, also known as E-type delayed fluorescence, see, e.g., U.S. application No. 15/700,352, which is incorporated herein by reference in its entirety), triplet-triplet annihilation, or a combination of these processes. In some embodiments, the emissive dopant may be a racemic mixture, or may be enriched in one enantiomer. In some embodiments, the compounds may be homoleptic (each ligand is the same). In some embodiments, the compounds may be compounded (at least one ligand being different from the others). In some embodiments, when there is more than one ligand that coordinates to the metal, the ligands may all be the same. In some other embodiments, at least one ligand is different from the other ligands. In some embodiments, each ligand may be different from each other. This is also true in embodiments where the ligand that coordinates to the metal can be linked to other ligands that coordinate to the metal to form a tridentate, tetradentate, pentadentate, or hexadentate ligand. Thus, where the coordinating ligands are linked together, in some embodiments all of the ligands may be the same, and in some other embodiments at least one of the linked ligands may be different from the other ligand(s).
In some embodiments, the compounds may be used as phosphorous photosensitizers in OLEDs, where one or more layers in the OLED contain an acceptor in the form of one or more fluorescent and/or delayed fluorescence emitters. In some embodiments, the compounds may be used as a component of an exciplex to be used as a sensitizer. As a phosphosensitizer, the compound must be capable of energy transfer to the acceptor and the acceptor will emit or further transfer energy to the final emitter. The receptor concentration may range from 0.001% to 100%. The acceptor may be in the same layer as the phosphorous sensitizer or in one or more different layers. In some embodiments, the receptor is a TADF emitter. In some embodiments, the acceptor is a fluorescent emitter. In some embodiments, the emission may be produced by any or all of the sensitizer, the receptor, and the final emitter.
According to another aspect, a formulation comprising a compound described herein is also disclosed.
The OLEDs disclosed herein can be incorporated into one or more of consumer products, electronic component modules, and lighting panels. The organic layer may be an emissive layer, and the compound may be an emissive dopant in some embodiments, while the compound may be a non-emissive dopant in other embodiments.
In yet another aspect of the present invention, a formulation comprising the novel compound disclosed herein is described. The formulation may include one or more of the components disclosed herein selected from the group consisting of: a solvent, a host, a hole injection material, a hole transport material, an electron blocking material, a hole blocking material, and an electron transport material.
The present disclosure encompasses any chemical structure comprising the novel compounds of the present disclosure or monovalent or multivalent variants thereof. In other words, the compounds of the present invention or monovalent or multivalent variants thereof may be part of a larger chemical structure. Such chemical structures may be selected from the group consisting of: monomers, polymers, macromolecules and supramolecules (also known as supramolecules). As used herein, "monovalent variant of a compound" refers to a moiety that is the same as a compound but where one hydrogen has been removed and replaced with a bond to the remainder of the chemical structure. As used herein, "multivalent variants of a compound" refers to moieties that are the same as a compound but where more than one hydrogen has been removed and replaced with one or more bonds to the rest of the chemical structure. In the case of supramolecules, the compounds of the invention may also be incorporated into supramolecular complexes without covalent bonds.
D. Combinations of the compounds of the present disclosure with other materials
Materials described herein as suitable for use in a particular layer in an organic light emitting device can be used in combination with a variety of other materials present in the device. For example, the emissive dopants disclosed herein may be used in conjunction with a wide variety of hosts, transport layers, barrier layers, implant layers, electrodes, and other layers that may be present. The materials described or referenced below are non-limiting examples of materials that can be used in combination with the compounds disclosed herein, and one of ordinary skill in the art can readily review the literature to identify other materials that can be used in combination.
a) Conductive dopant:
the charge transport layer may be doped with a conductivity dopant to substantially change its charge carrier density, which in turn will change its conductivity. The conductivity is increased by the generation of charge carriers in the host material and, depending on the type of dopant, a change in the Fermi level of the semiconductor can also be achieved. The hole transport layer may be doped with a p-type conductivity dopant and an n-type conductivity dopant is used in the electron transport layer.
Non-limiting examples of conductivity dopants that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified below: EP01617493, EP01968131, EP2020694, EP2684932, US20050139810, US20070160905, US20090167167, US2010288362, WO06081780, WO2009003455, WO2009008277, WO2009011327, WO2014009310, US2007252140, US2015060804, US20150123047 and US 2012146012.
Figure BDA0002963167840000901
Figure BDA0002963167840000911
b)HIL/HTL:
The hole injection/transport material used in the present disclosure is not particularly limited, and any compound may be used as long as the compound is generally used as the hole injection/transport material. Examples of materials include (but are not limited to): phthalocyanine or porphyrin derivatives; an aromatic amine derivative; indolocarbazole derivatives; a fluorocarbon-containing polymer; a polymer having a conductive dopant; conductive polymers such as PEDOT/PSS; self-assembling monomers derived from compounds such as phosphonic acids and silane derivatives; metal oxide derivatives, e.g. MoOx(ii) a p-type semiconducting organic compounds, such as 1,4,5,8,9, 12-hexaazatriphenylhexacyano-nitrile; a metal complex; and a crosslinkable compound.
Examples of aromatic amine derivatives for use in HILs or HTLs include, but are not limited to, the following general structures:
Figure BDA0002963167840000912
Ar1to Ar9Each of which is selected from: a group consisting of aromatic hydrocarbon cyclic compounds such as: benzene, biphenyl, terphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene,
Figure BDA0002963167840000913
Perylene and azulene; a group consisting of aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazoleOxazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, bisoxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzoselenenopyridine, and selenenopyridyl; and a group consisting of 2 to 10 cyclic structural units which are the same type or different types of groups selected from aromatic hydrocarbon ring groups and aromatic heterocyclic groups and are bonded to each other directly or via at least one of an oxygen atom, a nitrogen atom, a sulfur atom, a silicon atom, a phosphorus atom, a boron atom, a chain structural unit and an aliphatic ring group. Each Ar may be unsubstituted or may be substituted with a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, Ar1To Ar9Independently selected from the group consisting of:
Figure BDA0002963167840000921
wherein k is an integer from 1 to 20; x101To X108Is C (including CH) or N; z101Is NAr1O or S; ar (Ar)1Having the same groups as defined above.
Examples of metal complexes used in HILs or HTLs include, but are not limited to, the following general formulas:
Figure BDA0002963167840000922
wherein Met is a metal which may have an atomic weight greater than 40; (Y)101-Y102) Is a bidentate ligand, Y101And Y102Independently selected from C, N, O, P and S; l is101Is an ancillary ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal; and k' + k "is the maximum number of ligands that can be attached to the metal.
In one aspect, (Y)101-Y102) Is a 2-phenylpyridine derivative. In another aspect, (Y)101-Y102) Is a carbene ligand. In another aspect, Met is selected from Ir, Pt, Os and Zn. In another aspect, the metal complex has a structure comparable to Fc+A minimum oxidation potential in solution of less than about 0.6V for/Fc coupling.
Non-limiting examples of HIL and HTL materials that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified by the following: CN102702075, DE102012005215, EP01624500, EP0169861, EP01806334, EP01930964, EP01972613, EP01997799, EP02011790, EP02055700, EP02055701, EP1725079, EP2085382, EP2660300, EP650955, JP07-073529, JP2005112765, JP2007091, JP 2008021621687, JP2014-009196, KR 201188898, KR20130077473, TW 201139201139402, US06517957, US 2008220158242, US20030162053, US20050123751 751, US 20060282993, US 200602872 14579, US 201181874874, US20070278938, US 20080014014464 091091091, US20080106190, US 200907192605092385, US 12460352009071794392604335200356371798, WO 20120020120020135200353141563543544354435443544354435443544354435443544354435443544354435646, WO 200200352003520035563256325632563256325646, WO 20035200352003520035200435443544354435443544354435443544354435443544354435646, WO 200605646, WO 200605632563256325632563256325646, WO 2002002002002002002002002002002002002002004356325632563256325632563256325632563256325632563256325632563256325632567, WO 2004354435443435632563256325632563256325632563256325632563243544354434354435443544354435443544354435443544354435443541, WO 2002002002002002002002002002002002002002002002002002002002002002002002002002002004354435443544354435443544354435443544354435443544354435443544354435443544354435443544354435427, WO 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020060435443544354435443544354435427, WO 20020020020020020020020020020020020043544354435443544354435443544354435443544354435443544354435427, WO 20020020020020020020020020020020020020060435427, WO 20020020020020020020020060435427, WO 2002002002002006043544354435427, WO 2002002002002002002004354435427, WO 20043544354435427, WO 200200200200200604354435443544354435443544354435427, WO 200435443563256325632563256325632563256325632563256325632563256325632563256325632563256325632563256325632563256325632435427, WO 200200200200200200435427, WO 20020020020020020043200200200200200432002002002002004320043435427, WO 200435427, WO 20043200200200435427, WO 200200200435427, WO 200200200432004320020020020020043200435427, WO 200200200435427, WO 20043435427, WO 20020020020020020020020020020020020020020020020020043544320020020020020020043432004320043544354435427, WO 200200200200.
Figure BDA0002963167840000931
Figure BDA0002963167840000941
Figure BDA0002963167840000951
Figure BDA0002963167840000961
Figure BDA0002963167840000971
Figure BDA0002963167840000981
Figure BDA0002963167840000991
c)EBL:
An Electron Blocking Layer (EBL) may be used to reduce the number of electrons and/or excitons that leave the emissive layer. The presence of such a barrier layer in a device may result in substantially higher efficiency and/or longer lifetime compared to a similar device lacking a barrier layer. In addition, blocking layers can be used to limit the emission to the desired area of the OLED. In some embodiments, the EBL material has a higher LUMO (closer to the vacuum level) and/or higher triplet energy than the emitter closest to the EBL interface. In some embodiments, the EBL material has a higher LUMO (closer to the vacuum level) and/or higher triplet energy than one or more of the bodies closest to the EBL interface. In one aspect, the compound used in the EBL contains the same molecule or the same functional group as used in one of the hosts described below.
d) A main body:
the light-emitting layer of the organic EL device of the present disclosure preferably contains at least a metal complex as a light-emitting material, and may contain a host material using the metal complex as a dopant material. Examples of the host material are not particularly limited, and any metal complex or organic compound may be used as long as the triplet energy of the host is larger than that of the dopant. Any host material may be used with any dopant so long as the triplet criteria are met.
Examples of the metal complex used as the host preferably have the following general formula:
Figure BDA0002963167840001001
wherein Met is a metal; (Y)103-Y104) Is a bidentate ligand, Y103And Y104Independently selected from C, N, O, P and S; l is101Is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal; and k' + k "is the maximum number of ligands that can be attached to the metal.
In one aspect, the metal complex is:
Figure BDA0002963167840001002
wherein (O-N) is a bidentate ligand having a metal coordinated to the O and N atoms.
In another aspect, Met is selected from Ir and Pt. In another aspect, (Y)103-Y104) Is a carbene ligand.
In one aspect, the host compound contains at least one selected from the group consisting of: a group consisting of aromatic hydrocarbon cyclic compounds such as: benzene, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, perylene,
Figure BDA0002963167840001003
Perylene and azulene; a group consisting of aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzoselenenopyridine, and selenenopyridine; and a group consisting of 2 to 10 cyclic structural units which are the same type or different types of groups selected from aromatic hydrocarbon ring groups and aromatic heterocyclic groups and are bonded to each other directly or via at least one of an oxygen atom, a nitrogen atom, a sulfur atom, a silicon atom, a phosphorus atom, a boron atom, a chain structural unit and an aliphatic ring group. Each option in each group may be unsubstituted or may be substituted with a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, the host compound contains at least one of the following groups in the molecule:
Figure BDA0002963167840001011
wherein R is101Selected from the group consisting of: hydrogen, deuterium, halogenA group selected from the group consisting of a carbonyl group, an alkyl group, a cycloalkyl group, a heteroalkyl group, a heterocycloalkyl group, an aralkyl group, an alkoxy group, an aryloxy group, an amino group, a silyl group, an alkenyl group, a cycloalkenyl group, a heteroalkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an acyl group, a carboxylic acid, an ether, an ester, a nitrile, an isonitrile, a thio group, a sulfinyl group, a sulfonyl group, a phosphino group, and combinations thereof, and when it is an aryl group or a heteroaryl group, it has a similar definition as Ar mentioned above. k is an integer from 0 to 20 or from 1 to 20. X101To X108Independently selected from C (including CH) or N. Z101And Z102Independently selected from NR101O or S.
Non-limiting examples of host materials that can be used in OLEDs in combination with the materials disclosed herein are exemplified below, along with references disclosing those materials: EP2034538, EP2034538A, EP2757608, JP2007254297, KR20100079458, KR20120088644, KR20120129733, KR20130115564, TW201329200, US20030175553, US20050238919, US20060280965, US20090017330, US20090030202, US20090167162, US20090302743, US20090309488, US20100012931, US20100084966, US20100187984, US2010187984, US2012075273, US2012126221, US2013009543, US2013105787, US2013175519, US 001446, US 20148301503, US20140225088, US2014034914, US7154114, WO2001039234, WO 2004093203203203207, WO 2005014545454545452009020090455646, WO 2002012009020120090201902019072201200907220120020190722012002012002016072201200201200201200201607246, WO 20120020120020160722012002016072201200201200201607246, WO 200201200201200201200201200201200201200201200907220020120020120020120020120020120020120090729, WO 200201200201200201200201200201200201200201200201200201200201200201200201200201200201200201200201200200200201200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200201200200200200201200201200200200200200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200201200201200200200200200200200200200200200200200200200200200201200201200200200201200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200201200201200200200200200200201200200201200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200,
Figure BDA0002963167840001021
Figure BDA0002963167840001031
Figure BDA0002963167840001041
Figure BDA0002963167840001051
Figure BDA0002963167840001061
Figure BDA0002963167840001071
e) other emitters:
one or more other emitter dopants may be used in combination with the compounds of the present invention. Examples of the other emitter dopant are not particularly limited, and any compound may be used as long as the compound is generally used as an emitter material. Examples of suitable emitter materials include, but are not limited to, compounds that can produce emission via phosphorescence, fluorescence, thermally activated delayed fluorescence (i.e., TADF, also known as E-type delayed fluorescence), triplet-triplet annihilation, or a combination of these processes.
Non-limiting examples of emitter materials that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified below: CN103694277, CN1696137, EB01238981, EP01239526, EP01961743, EP1239526, EP1244155, EP1642951, EP1647554, EP1841834, EP1841834B, EP2062907, EP2730583, JP 201207440263, JP4478555, KR1020090133652, KR20120032054, KR20130043460, TW201332980, US0669959, US 200100916520, US20010019782, US20020034656, US 20030068568526, US20030072964, US 2003013865657, US 200501787878788, US 20020020020020120044673, US2005123791, US 2006052449 449, US20060008670, US20060065890, US 601696, US 6016016016012006012016016310204659, US 2012002012002012002012002012000477817781979, WO 20020120020120020120020020020020020020004778177819748, US 20120020020004779, WO 200200200201200201200200200200200201200778177819748, US 20020120004779, US 20120020120020120020120020020120020020020004779, US 2002012002002002002002002002002002002002002002002002002002012000477819748, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 20020020020020020020020020020020020020020020020020020020120020120020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020120020120020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020120020120020020020020020020020020020020020020020020020020020020020020020020020020020020120020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020120020120020120020120043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, the No. 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200979, the No. 10,979, the No. 10,979, the No. 10, the No. 10,979, the No. 10,979, No. 10, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200, WO2012020327, WO2012163471, WO2013094620, WO2013107487, WO2013174471, WO2014007565, WO2014008982, WO2014023377, WO2014024131, WO2014031977, WO2014038456, WO 2014112450.
Figure BDA0002963167840001081
Figure BDA0002963167840001091
Figure BDA0002963167840001101
Figure BDA0002963167840001111
Figure BDA0002963167840001121
Figure BDA0002963167840001131
f)HBL:
Hole Blocking Layers (HBLs) may be used to reduce the number of holes and/or excitons that leave the emissive layer. The presence of such a barrier layer in a device may result in substantially higher efficiency and/or longer lifetime compared to a similar device lacking a barrier layer. In addition, blocking layers can be used to limit the emission to the desired area of the OLED. In some embodiments, the HBL material has a lower HOMO (farther from the vacuum level) and/or higher triplet energy than the emitter closest to the HBL interface. In some embodiments, the HBL material has a lower HOMO (farther from the vacuum level) and/or higher triplet energy than one or more of the hosts closest to the HBL interface.
In one aspect, the compound used in the HBL contains the same molecule or the same functional group as used for the host described above.
In another aspect, the compound used in HBL contains in the molecule at least one of the following groups:
Figure BDA0002963167840001132
wherein k is an integer from 1 to 20; l is101Is another ligand, and k' is an integer of 1 to 3.
g)ETL:
The Electron Transport Layer (ETL) may include a material capable of transporting electrons. The electron transport layer may be intrinsic (undoped) or doped. Doping may be used to enhance conductivity. Examples of the ETL material are not particularly limited, and any metal complex or organic compound may be used as long as it is generally used to transport electrons.
In one aspect, the compound used in the ETL contains in the molecule at least one of the following groups:
Figure BDA0002963167840001133
wherein R is101Selected from the group consisting of: hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof, which when aryl or heteroaryl has a similar definition to Ar described above. Ar (Ar)1To Ar3Have similar definitions as Ar mentioned above. k is an integer of 1 to 20. X101To X108Selected from C (including CH) or N.
In another aspect, the metal complex used in the ETL contains (but is not limited to) the following general formula:
Figure BDA0002963167840001141
wherein (O-N) or (N-N) is a bidentate ligand having a metal coordinated to atom O, N or N, N; l is101Is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal.
Non-limiting examples of ETL materials that can be used in an OLED in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified as follows: CN103508940, EP01602648, EP01734038, EP01956007, JP2004-022334, JP2005149918, JP2005-268199, KR0117693, KR20130108183, US20040036077, US20070104977, US2007018155, US20090101870, US20090115316, US20090140637, US 2009017959554, US2009218940, US2010108990, US2011156017, US2011210320, US2012193612, US2012214993, US 20140142014014925, US 201401492014927, US 2014028450284580, US 5666612, US 1508431, WO 200306093060979256, WO2007111263, WO2009148269, WO2010067894, WO2010072300, WO 201107070, WO 105373, WO 201303017, WO 201314545477, WO 2014545667, WO 201104376, WO2014104535, WO 2014535,
Figure BDA0002963167840001142
Figure BDA0002963167840001151
Figure BDA0002963167840001161
h) charge Generation Layer (CGL)
In tandem or stacked OLEDs, CGL plays a fundamental role in performance, consisting of an n-doped layer and a p-doped layer for injecting electrons and holes, respectively. Electrons and holes are supplied by the CGL and the electrodes. Electrons and holes consumed in the CGL are refilled by electrons and holes injected from the cathode and anode, respectively; subsequently, the bipolar current gradually reaches a steady state. Typical CGL materials include n and p conductivity dopants used in the transport layer.
In any of the above-mentioned compounds used in each layer of the OLED device, the hydrogen atoms may be partially or fully deuterated. Thus, any of the specifically listed substituents, such as (but not limited to) methyl, phenyl, pyridyl, and the like, can be in their non-deuterated, partially deuterated, and fully deuterated forms. Similarly, substituent classes (such as, but not limited to, alkyl, aryl, cycloalkyl, heteroaryl, etc.) can also be non-deuterated, partially deuterated, and fully deuterated forms thereof.
It should be understood that the various embodiments described herein are by way of example only and are not intended to limit the scope of the invention. For example, many of the materials and structures described herein may be substituted with other materials and structures without departing from the spirit of the invention. The invention as claimed may thus comprise variations of the specific examples and preferred embodiments described herein, as will be apparent to those skilled in the art. It should be understood that various theories as to why the invention works are not intended to be limiting.
Experimental data
Density Functional Theory (DFT) data
Calculations were performed using the B3LYP functional with the CEP-31G base set. Geometric optimization was performed in vacuum. Excitation energy at these optimized geometries was obtained using time-dependent density functional theory (TDDFT). A continuous solvent model was applied in the TDDFT calculation to simulate tetrahydrofuran solvent. All calculations were performed using the program Gaussian (Gaussian). Table 3 shows HOMO and LUMO, along with the corresponding HOMO-LUMO energy gap and the corresponding singlet S1And triplet T1Calculated value of the wavelength of the light of the transition.
TABLE 3
Figure BDA0002963167840001171
Figure BDA0002963167840001181
Figure BDA0002963167840001191
The DFT results indicate that the emission of the compounds of the invention is blue shifted relative to the comparative compound. This fine tuning of the emission color is very important in the design of the emitting OLED material.
The calculations obtained using the set of DFT functions and the base set identified above are theoretical. Computing the combination protocol (gauss 09 with B3LYP and CEP-31G protocols as used herein) relies on the following assumptions: the electronic effects are additive and therefore Complete Basis Set (CBS) limits can be extrapolated using larger basis sets. However, when the objective of the study is to understand the HOMO, LUMO, S of a series of structurally related compounds1、T1The additive effect is expected to be similar when the bond dissociation energy, etc. varies. Thus, while the absolute error using B3LYP may be significant compared to other calculation methods, HOMO, LUMO, S calculated using the B3LYP protocol are expected1、T1And the relative difference between the bond dissociation energy values are expected to reproduce the experiment well. See, e.g., Hong et al, material chemistry (chem. mater.)2016,28, 5791-. Furthermore, with respect to iridium or platinum complexes suitable for use in the OLED field, the data obtained from the DFT calculation is closely related to actual experimental data. See tawasie et al, journal of materials chemistry (j. mater. chem.)2012,22,6419-29,6422 (table 3) (showing DFT calculations closely related to actual data for various emission complexes); morelalo (Morello), g.r., journal of molecular modeling (j.mol.model.)2017,23:174 (studying various sets of DFT functions and basis sets and concluding that the combination of B3LYP and CEP-31G is particularly accurate for emissive complexes).

Claims (20)

1. A compound comprising a ligand L having the structure of formula IA
Figure FDA0002963167830000011
Wherein:
ring a is a 6-membered aromatic ring;
ring D is a monocyclic or polycyclic fused ring system comprising one or more 5-or 6-membered carbocyclic or heterocyclic rings;
k is selected from the group consisting of: a direct bond, O and S;
RArepresents zero substitution, mono substitution, or up to the maximum permissible substitution of its associated ring;
RDrepresents a disubstituted or up to the maximum permissible substitution of its associated ring;
at least two adjacent RDForming condensed with DA structure of formula II below;
formula II
Figure FDA0002963167830000012
Z1Selected from the group consisting of: o, S, Se, NR and SiRR';
Z2is N;
each RA、RB、RDR, R' and R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, oxyboronyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof;
the ligand LAComplexed with a metal M through a dotted line to form a 5-membered chelate ring;
m is selected from the group consisting of: ir, Rh, Re, Ru, Os, Pt, Pd, Au and Cu;
m may coordinate to other ligands;
LAcan be linked to other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
RA、RB、RDAny two of R and R' may be joined or fused to form a ring, and RA、RDAny of R and R' may be joined or fused to R "to form a ring.
2. The compound of claim 1, wherein each RA、RB、RDR and R' are independently hydrogen or a substituent selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, oxyboronyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof.
3. The compound of claim 1Wherein R isBSelected from the group consisting of: hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
4. The compound of claim 1, wherein RBSelected from the group consisting of:
Figure FDA0002963167830000021
Figure FDA0002963167830000022
5. the compound of claim 1, wherein ring D is selected from the group consisting of: phenyl, naphthalene, anthracene, benzofuran, benzothiophene, dibenzofuran, dibenzothiophene, and aza variants thereof; and ring a is selected from the group consisting of: pyridine, pyrimidine, pyridazine, quinoline, isoquinoline, quinoxaline, quinazoline, thienopyridine, thienopyrimidine, thienopyridazine, azabiphenyl furan, azabiphenyl thiophene, azabenzofuran, and azabenzothiophene.
6. The compound of claim 1, wherein the structure of formula II is selected from the group consisting of:
Figure FDA0002963167830000031
Figure FDA0002963167830000041
7. the compound of claim 1, wherein LASelected from the group consisting of:
Figure FDA0002963167830000042
Figure FDA0002963167830000051
Figure FDA0002963167830000061
Z1'o, S, CH or NCH3 Z2'、Z3'、Z4'Either C or N
Figure FDA0002963167830000071
Figure FDA0002963167830000081
Figure FDA0002963167830000091
Figure FDA0002963167830000101
Figure FDA0002963167830000111
Figure FDA0002963167830000121
Figure FDA0002963167830000131
Wherein Z1'=O、SOr NCH3;Z2'、Z3'、Z4′C or N; and Z is5'=O、N、S、Si(CH3)2Or C (CH)3)2
8. The compound of claim 1, wherein LAIs selected from the group consisting of LAi-mWherein i is an integer from 1 to 2100 and m is an integer from 1 to 66, wherein LAi-1To LAi-66The structure of (a) is as follows:
Figure FDA0002963167830000132
Figure FDA0002963167830000141
Figure FDA0002963167830000151
Figure FDA0002963167830000161
Figure FDA0002963167830000171
Figure FDA0002963167830000181
wherein each LAiR of (A) to (B)AAnd RBThe definition is as follows:
Figure FDA0002963167830000182
Figure FDA0002963167830000191
Figure FDA0002963167830000201
Figure FDA0002963167830000211
Figure FDA0002963167830000221
Figure FDA0002963167830000231
Figure FDA0002963167830000241
Figure FDA0002963167830000251
Figure FDA0002963167830000261
Figure FDA0002963167830000271
wherein R isA1To RA70Has the following structure:
Figure FDA0002963167830000272
Figure FDA0002963167830000273
Figure FDA0002963167830000281
Figure FDA0002963167830000291
Figure FDA0002963167830000301
wherein R isB1To RB30Has the following structure:
Figure FDA0002963167830000311
9. the compound of claim 1, wherein the compound has a formula selected from the group consisting of: ir (L)A)3、Ir(LA)(LB)2、Ir(LA)2(LB)、Ir(LA)2(LC) And Ir (L)A)(LB)(LC) (ii) a And wherein LA、LBAnd LCAre different from each other; and L isBAnd LCEach independently selected from the group consisting of:
Figure FDA0002963167830000312
Figure FDA0002963167830000321
wherein:
t is B, Al, Ga or In;
Y1to Y13Each of which is independently selected from the group consisting of C and N;
y' is selected from the group consisting of: BR (BR)e、NRe、PRe、O、S、Se、C=O、S=O、SO2、CReRf、SiReRfAnd GeReRf
ReAnd RfMay be fused or joined to form a ring;
each Ra、Rb、RcAnd RdIndependently represent zero substitution, mono substitution, or up to the maximum allowed number of substitutions for its associated ring;
Ra1、Rb1、Rc1、Rd1、Ra、Rb、Rc、Rd、Reand RfEach of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, halo, alkyl, cycloalkyl, heteroalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; general substituents as defined herein; and is
Any two adjacent Ra、Rb、Rc、Rd、ReAnd RfMay be fused or joined to form a ring or to form a multidentate ligand.
10. The compound of claim 9, wherein LBIs a substituted or unsubstituted phenylpyridine, and LCIs a substituted or unsubstituted acetyl acetonate radical.
11. The compound of claim 1, whereinWhen the compound has the formula Ir (L)Ai-m)3When i is an integer of 1 to 2100, m is an integer of 1 to 66, and the compound is selected from the group consisting of Ir (L)A1-1)3To Ir (L)A2100-66)3A group of compounds;
when the compound has the formula Ir (L)Ai-m)(LBk)2When i is an integer of 1 to 2100, m is an integer of 1 to 66, k is an integer of 1 to 270, and the compound is selected from the group consisting of Ir (L)A1-1)(LB1)2To Ir (L)A2100-66)(LB270)2A group of compounds;
when the compound has the formula Ir (L)Ai-m)2(LBk) When i is an integer of 1 to 2100, m is an integer of 1 to 66, k is an integer of 1 to 270, and the compound is selected from the group consisting of Ir (L)A1-1)2(LB1) To Ir (L)A2100-66)2(LB270) A group of compounds;
when the compound has the formula Ir (L)Ai-m)2(LCj-I) When i is an integer from 1 to 2100, m is an integer from 1 to 66, j is an integer from 1 to 1416, and the compound is selected from the group consisting of Ir (L)A1-1)2(LC1-I) To Ir (L)A2100-66)2(LC1416-I) A group of compounds; and is
When the compound has the formula Ir (L)Ai-m)2(LCj-II) When i is an integer from 1 to 2100, m is an integer from 1 to 66, j is an integer from 1 to 1416, and the compound is selected from the group consisting of Ir (L)A1-1)2(LC1-II) To Ir (L)A2100-66)2(LC1416-II) A group of combinations thereof.
12. The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure FDA0002963167830000341
Figure FDA0002963167830000351
Figure FDA0002963167830000361
Figure FDA0002963167830000371
Figure FDA0002963167830000381
Figure FDA0002963167830000391
13. the compound of claim 1, wherein the compound has
Figure FDA0002963167830000392
Wherein:
M1is Pd or Pt;
rings E and F are each independently a 5-or 6-membered carbocyclic or heterocyclic ring;
Z1and Z2Each independently is C or N;
K1and K2Each independently selected from the group consisting of: a direct bond, O and S, wherein K1And K2At least one of which is a direct bond;
L1、L2and L3Each independently selected from the group consisting of: a single bond, absent a bond, O, S, CR 'R ", SiR' R", BR ', CR ═ CR ", and NR', wherein L is1、L2And L3Is present;
REand RFEach independently represents zero substitution, mono substitution, or up to the maximum permissible substitution for its associated ring;
R'、R”、REand RFEach of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof;
any two RA、RD、RE、RFR 'and R' may be joined or fused to form a ring when chemically feasible; and is
RA、RDK and rings A and D are all as defined above.
14. The compound of claim 13, wherein ring E and ring F are both 6-membered aromatic rings, and ring F is a 5-or 6-membered heteroaromatic ring.
15. The compound of claim 13, wherein the compound is selected from the group consisting of:
Figure FDA0002963167830000401
Figure FDA0002963167830000411
wherein:
two adjacent RDForming a structure of formula II fused to D;
formula II
Figure FDA0002963167830000421
RxAnd RyAre each selected fromA group consisting of: alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, heteroaryl, and combinations thereof;
RGindependently at each occurrence is hydrogen or a substituent selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof; and is
RA、RB、RE、RF、Z1、Z2、K、L1Rings a and D are all as defined above.
16. The compound of claim 13, wherein the compound is selected from the group consisting of:
Figure FDA0002963167830000422
Figure FDA0002963167830000431
Figure FDA0002963167830000441
Figure FDA0002963167830000451
Figure FDA0002963167830000461
17. an Organic Light Emitting Device (OLED), comprising:
an anode;
a cathode; and
an organic layer disposed between the anode and the cathode containing a ligand L comprising a structureAThe compound of (1):
formula I
Figure FDA0002963167830000462
Wherein:
ring a is a 6-membered aromatic ring;
ring D is a monocyclic or polycyclic fused ring system comprising one or more 5-or 6-membered carbocyclic or heterocyclic rings;
k is selected from the group consisting of: a direct bond, O and S;
RArepresents zero substitution, mono substitution, or up to the maximum permissible substitution of its associated ring;
RDrepresents a disubstituted or up to the maximum permissible substitution of its associated ring;
at least two adjacent RDForming a structure of formula II fused to D;
Figure FDA0002963167830000471
Z1selected from the group consisting of: o, S, Se, NR and SiRR';
Z2is N;
each RA、RB、RDR, R' and R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, oxyboronyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof;
the ligand LAComplexed with a metal M through a dotted line to form a 5-membered chelate ring;
m is selected from the group consisting of: ir, Rh, Re, Ru, Os, Pt, Pd, Au and Cu;
m may coordinate to other ligands;
LAcan be linked to other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
RA、RB、RDAny two of R and R' may be joined or fused to form a ring, and RA、RDAny of R and R' may be joined or fused to R "to form a ring.
18. The OLED of claim 17, wherein the organic layer further comprises a host, wherein the host comprises at least one chemical moiety selected from the group consisting of: naphthalene, fluorene, triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5, 9-dioxa-13 b-boranaphtho [3,2,1-de ] anthracene and aza variants thereof.
19. The OLED of claim 17, wherein the organic layer further comprises a host, wherein the host is selected from the group consisting of:
Figure FDA0002963167830000472
Figure FDA0002963167830000481
Figure FDA0002963167830000491
Figure FDA0002963167830000492
and combinations thereof.
20. A consumer product comprising an organic light emitting device, the organic light emitting device comprising:
an anode;
a cathode; and
an organic layer disposed between the anode and the cathode containing a ligand L comprising a structure having formula IAThe compound of (1):
Figure FDA0002963167830000493
wherein:
ring a is a 6-membered aromatic ring;
ring D is a monocyclic or polycyclic fused ring system comprising one or more 5-or 6-membered carbocyclic or heterocyclic rings;
k is selected from the group consisting of: a direct bond, O and S;
RArepresents zero substitution, mono substitution, or up to the maximum permissible substitution of its associated ring;
RDrepresents a disubstituted or up to the maximum permissible substitution of its associated ring;
at least two adjacent RDForming a structure of formula II fused to D;
Figure FDA0002963167830000501
Z1selected from the group consisting of: o, S, Se, NR and SiRR';
Z2is N;
each RA、RB、RDR, R' and R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, oxyboronyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof;
the ligand LAComplexed with a metal M through a dotted line to form a 5-membered chelate ring;
m is selected from the group consisting of: ir, Rh, Re, Ru, Os, Pt, Pd, Au and Cu;
m may coordinate to other ligands;
LAcan be linked to other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
RA、RB、RDAny two of R and R' may be joined or fused to form a ring, and RA、RDAny of R and R' may be joined or fused to R "to form a ring.
CN202110243480.4A 2020-03-06 2021-03-05 Organic electroluminescent material and device Pending CN113354687A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062986026P 2020-03-06 2020-03-06
US62/986,026 2020-03-06
US202063082774P 2020-09-24 2020-09-24
US63/082,774 2020-09-24
US17/179,952 2021-02-19
US17/179,952 US20210288269A1 (en) 2020-03-06 2021-02-19 Organic electroluminescent materials and devices

Publications (1)

Publication Number Publication Date
CN113354687A true CN113354687A (en) 2021-09-07

Family

ID=77524881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110243480.4A Pending CN113354687A (en) 2020-03-06 2021-03-05 Organic electroluminescent material and device

Country Status (1)

Country Link
CN (1) CN113354687A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109722A1 (en) * 2021-12-14 2023-06-22 广东阿格蕾雅光电材料有限公司 Platinum complex light-emitting material based on carbazole modification and application thereof
CN116284143A (en) * 2022-09-09 2023-06-23 季华恒烨(佛山)电子材料有限公司 Platinum complex and organic electroluminescent device comprising same
WO2023241137A1 (en) * 2022-06-13 2023-12-21 陕西莱特光电材料股份有限公司 Nitrogen-containing compound, organic electroluminescent apparatus, and electronic device

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008093546A (en) * 2006-10-10 2008-04-24 Kn Lab Analysis:Kk Tunnel type washing apparatus
JP2016219490A (en) * 2015-05-15 2016-12-22 コニカミノルタ株式会社 Organic electroluminescent element, display device and illuminating device
CN108059645A (en) * 2016-11-09 2018-05-22 环球展览公司 Electroluminescent organic material and device
CN108424427A (en) * 2011-07-25 2018-08-21 通用显示公司 Four tooth platinum complexes
US20180309067A1 (en) * 2017-04-21 2018-10-25 Universal Display Corporation Organic electroluminescent materials and devices
CN109796499A (en) * 2017-11-17 2019-05-24 北京夏禾科技有限公司 The metal complex of nitrogen-containing hetero benzothiazole
US20190341562A1 (en) * 2018-05-04 2019-11-07 Universal Display Corporation Organic electroluminescent materials and devices

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008093546A (en) * 2006-10-10 2008-04-24 Kn Lab Analysis:Kk Tunnel type washing apparatus
CN108424427A (en) * 2011-07-25 2018-08-21 通用显示公司 Four tooth platinum complexes
JP2016219490A (en) * 2015-05-15 2016-12-22 コニカミノルタ株式会社 Organic electroluminescent element, display device and illuminating device
CN108059645A (en) * 2016-11-09 2018-05-22 环球展览公司 Electroluminescent organic material and device
US20180309067A1 (en) * 2017-04-21 2018-10-25 Universal Display Corporation Organic electroluminescent materials and devices
CN109796499A (en) * 2017-11-17 2019-05-24 北京夏禾科技有限公司 The metal complex of nitrogen-containing hetero benzothiazole
US20190341562A1 (en) * 2018-05-04 2019-11-07 Universal Display Corporation Organic electroluminescent materials and devices

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109722A1 (en) * 2021-12-14 2023-06-22 广东阿格蕾雅光电材料有限公司 Platinum complex light-emitting material based on carbazole modification and application thereof
WO2023241137A1 (en) * 2022-06-13 2023-12-21 陕西莱特光电材料股份有限公司 Nitrogen-containing compound, organic electroluminescent apparatus, and electronic device
CN116284143A (en) * 2022-09-09 2023-06-23 季华恒烨(佛山)电子材料有限公司 Platinum complex and organic electroluminescent device comprising same

Similar Documents

Publication Publication Date Title
CN113354687A (en) Organic electroluminescent material and device
CN115073527A (en) Organic electroluminescent material and device
CN114230613A (en) Organic electroluminescent material and device
CN113717230A (en) Organic electroluminescent material and device
CN117447523A (en) Organic electroluminescent material and device
CN116425801A (en) Organic electroluminescent material and device
CN116003471A (en) Organic electroluminescent material and device
CN115536706A (en) Organic electroluminescent material and device
CN114349793A (en) Organic electroluminescent material and device
CN114957337A (en) Organic electroluminescent material and device
CN114853815A (en) Organic electroluminescent material and device
CN113248544A (en) Organic electroluminescent material and device
KR20210113956A (en) Organic electroluminescent materials and devices
KR20230131447A (en) Organic electroluminescent materials and devices
CN115260247A (en) Organic electroluminescent material and device
CN114149468A (en) Organic electroluminescent material and device
CN115433239A (en) Organic electroluminescent material and device
CN115724892A (en) Organic electroluminescent material and device
KR20230022135A (en) Organic electroluminescent materials and devices
CN117586314A (en) Organic electroluminescent material and device
CN115960140A (en) Organic electroluminescent material and device
CN115504998A (en) Organic electroluminescent material and device
CN115974930A (en) Organic electroluminescent material and device
CN115960143A (en) Organic electroluminescent material and device
KR20240024759A (en) Organic electroluminescent materials and devices

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination